Fusion molecule based on taa variant
US-2018228882-A1 · Aug 16, 2018 · US
containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K2319/75 |
| Official title | containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones |
| Display label | containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones |
| Total patents | 240 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 16 |
| 2016 | 17 |
| 2017 | 26 |
| 2018 | 21 |
| 2019 | 29 |
| 2020 | 23 |
| 2021 | 13 |
| 2022 | 38 |
| 2023 | 23 |
| 2024 | 14 |
| 2025 | 19 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Met receptor agonist proteins
US-2017369545-A1 · Dec 28, 2017 · US
Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
US-2017355739-A1 · Dec 14, 2017 · US
Methods of using fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods to reduce blood glucose
US-2017355740-A1 · Dec 14, 2017 · US
Polypeptide hydrogels and uses related thereto
US-9840693-B2 · Dec 12, 2017 · US
METHOD OF HIGHLY EXPRESSING TARGET PROTEIN FROM PLANT USING RbcS FUSION PROTEIN AND METHOD OF PREPARING COMPOSITION FOR ORAL ADMINISTRATION OF MEDICAL PROTEIN USING TARGET PROTEIN EXPRESSION PLANT BODY
US-2017335361-A1 · Nov 23, 2017 · US
Chimeric protein
US-2017335311-A1 · Nov 23, 2017 · US
Targeted therapeutic proteins
US-9814762-B2 · Nov 14, 2017 · US
Cytokine-based fusion proteins for treatment of immune disorders
US-2017320933-A1 · Nov 9, 2017 · US
VLPS Containing Ligands and Methods Related Thereto
US-2017290906-A1 · Oct 12, 2017 · US
Modified microbial toxin receptor for delivering agents into cells
US-2017283471-A1 · Oct 5, 2017 · US
T-Cell Redirecting Bispecific Antibodies for Treatment of Disease
US-2017247417-A1 · Aug 31, 2017 · US
Cytokine-based fusion proteins for treatment of immune disorders
US-9745361-B2 · Aug 29, 2017 · US
Methods and compositions using klotho-fgf fusion polypeptides
US-2017233446-A1 · Aug 17, 2017 · US
Fgf23 fusion proteins
US-2017226172-A1 · Aug 10, 2017 · US
Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same
US-2017216460-A1 · Aug 3, 2017 · US
Modified microbial toxin receptor for delivering agents into cells
US-9708374-B2 · Jul 18, 2017 · US
FGF21 Receptor Agonists And Uses Thereof
US-2017174769-A1 · Jun 22, 2017 · US
VLPS containing ligands and methods related thereto
US-9683020-B2 · Jun 20, 2017 · US
Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
US-2017166651-A1 · Jun 15, 2017 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K2319/75?
- CPC C07K2319/75 is the Cooperative Patent Classification code for “containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones.”
- How many patents are filed under CPC C07K2319/75 (containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones)?
- Our database includes 240 publications tagged with this CPC code.
- Is patent activity under CPC C07K2319/75 growing?
- Publication counts under this code: 14 in 2024 vs 19 in 2025 (latest complete years).